Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 5/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16303439 | 1.00 | KDM4E (0.70) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL28958163 | 1.00 | KDM4E (0.70) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL885320 | 0.98 | KDM4E (0.65) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL427283 | 0.91 | KDM4E (0.61) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL25478737 | 0.90 | KDM4E (0.61) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL25837278 | 0.87 | KDM4E (0.70) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL14739904 | 0.83 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL1847535 | 0.83 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL14740196 | 0.83 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL1900654 | 0.83 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
| WO-2011121105-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TYMP, PIM1, TYMS | KDM4E 911/4885MAPK1 2190/4885HIF1A 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.